Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK

BACKGROUND: Emerging evidence demonstrated dapagliflozin (DAPA), a sodium-glucose cotransporter 2 inhibitor, prevented various cardiovascular events. However, the detailed mechanisms underlying its cardioprotective properties remained largely unknown. RESULTS: In the present study, we sought to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Kun-Ling, Hsieh, Pei-Ling, Chou, Wan-Ching, Cheng, Hui-Ching, Huang, Yu-Ting, Chan, Shih-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913252/
https://www.ncbi.nlm.nih.gov/pubmed/33637129
http://dx.doi.org/10.1186/s13578-021-00547-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913252/
https://www.ncbi.nlm.nih.gov/pubmed/33637129
http://dx.doi.org/10.1186/s13578-021-00547-y

Ejemplares similares